TORONTO, ONTARIO — (Aug 10, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that the report on their Phase I studies of ATB-346, its lead drug, has been finalized. This milestone permits Antibe to proceed, when appropriate, with filing of applications to appropriate regulators for Phase II studies of ATB-346.
In Phase I, ATB-346 was found to be safe and well tolerated at a daily dose of 250 mg for 14 days. At this dose, and doses as low as 75 mg daily, ATB-346 markedly inhibited the enzyme cyclooxygenase (COX), which is the target of nonsteroidal anti-inflammatory drugs: the degree of inhibition of COX activity correlates well with reduction of pain and inflammation. The inhibition of COX by ATB-346 persisted for 24 hours after administration, suggesting a once-daily dosing regimen for this drug of 250 mg or less.
As recently announced, Antibe’s ongoing validation studies of ATB-346 are progressing on schedule. These studies are aimed at gaining a better understanding of the absorption, excretion and key metabolites of ATB-346 after oral administration. The studies are being performed by Covance Laboratories, in the USA, using laboratory rats. The rats were treated with ATB-346 to which a radioactive label had been applied. This allows for tracking of the non-naproxen portion of the drug. The single-dosing portion of the study has been completed; data collected thus far demonstrate that over 93% of the non-naproxen portion of ATB-346 was cleared from the body within 24 hours of oral administration. A multiple-dosing study is in progress.
Antibe will continue to keep the market informed of progress in the ongoing validation studies, the results of which remain on schedule for Q4.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com
Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
dan.legault@antibethera.com
Read all news